Stock Watch: How The Pandemic Impact On Pharma’s Value Chain Is Mutating
Emerging Challenges Threaten Manufacturing, Supply And Regulatory Decision-Making
From clinical trials to in-person sales calls, the pharmaceutical value chain has been tested by the COVID-19 pandemic, but has held up. Nevertheless, recent friction within this chain may be more than a passing irritation.
You may also be interested in...
Virtual marketing was the logical way to interact with healthcare professionals during the pandemic. It may stay after the pandemic but could be an additional expense.
Takeda and Moderna have identified the source of metallic particles in some lots of mRNA-1273 in Japan, but believe the two deaths identified to be coincidental. Pfizer starts protease inhibitor trial, and Rigel reports fostamatinib data.
It takes a lot of negotiation with regulators, advisory boards, and alignment between commercial and portfolio management teams to define and agree a clinical trial protocol. Why on earth would companies change it once a study is underway?